FIELD: pharmaceutics.
SUBSTANCE: group of inventions refers to pharmaceutical industry. Method of treating neurological condition in a subject including the administration to a subject in need thereof, composition containing an extract fraction of Nerium species or Thevetia species in an amount effective for treating a neurological condition, where the fraction extract contains at least one steroid, not containing cardiac glycoside components, oleanolic acid, ursolic acid and betulinic acid and does not include oleandrine and neriifolin, where the fraction was received by a chromatographic fractionation of the extract. Method of treating neurological condition in a subject. Fraction of the extract of Nerium species or Thevetia species, for use in treating neurological pathological condition in a subject. Pharmaceutical composition for treating neurological condition in a subject. Method of improving the clinical condition of a statistically significant number of subjects in a group of subjects having neurological condition. Method of preventing or reducing the probability of neurological condition in a group of subjects. Method of delayed in time treatment of stroke in a subject. Method of producing a fraction extract of Nerium species or Thevetia species. Composition for treating Alzheimer's disease, Huntington's disease, stroke, taupathy or condition, having an etiology associated with excessive proteolysis of amyloid beta precursor protein, with accumulation of amyloid beta protein in the synapses of the neurons.
EFFECT: above group of inventions enables to obtain and to use the fraction of Nerium species or Thevetia species, having considerable neuroprotective efficiency despite the fact, that in this fraction is absent oleandrine, neriifolin and polysaccharides of types of Nerium species or Thevetia species.
30 cl, 20 dwg, 1 tbl, 18 ex
